Delivery Order SPE2DB24D1201-SPE2DB25FJDQE
Award Date 7/24/25
Potential Completion Date 7/25/25
Potential Value $31K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $6,032.22 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of June 20, 2025. This non-set-aside competitive award was issued on June 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. ENBREL is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory conditions, making this a specialized...
- The Defense Logistics Agency awarded a $31,043.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 5, 2025. This non-set-aside award was made competitively and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion vehicle running through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,778.84 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This non-set-aside, firm fixed price delivery order was awarded on September 4, 2025, with an ultimate completion date of September 5, 2025. Performance will occur at the vendor's location in Conshohocken, Pennsylvania. Enbrel is a biologic immunosuppressant medication commonly used to treat rheumatoid arthritis and other inflammatory...
- The Defense Logistics Agency awarded a $5,580.50 delivery order to AmerisourceBergen Drug Corp on May 28, 2025, for the supply of ENBREL 50 mg/ml syringes. This contract represents a firm fixed-price delivery order with an ultimate completion date of May 29, 2025, and is classified as a non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. ENBREL is a biologic pharmaceutical used in the treatment of rheumatoid arthritis and other...
- The Defense Logistics Agency awarded a delivery order valued at $20,608.70 to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL syringes, with an ultimate completion date of August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a $10,064.15 delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of ENBREL 50 mg/mL syringes. This is a firm fixed-price contract with no set-aside designation, competitively awarded under AmerisourceBergen's existing federal procurement framework. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of May 9, 2025. ENBREL is a biopharmaceutical product used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes valued at $68,950.48 on September 12, 2025, with completion targeted for September 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 ceiling and extends through December 2026. The place of...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $10,276.74 for ENBREL 50 mg/mL SureClick auto-injectors on September 4, 2025, with completion scheduled for September 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. ENBREL is a biologic immunosuppressant used to treat rheumatoid arthritis, psoriasis, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $28,464.40 to supply Enbrel 50 mg/mL SureClick prefilled syringes. This firm fixed-price delivery order, which was not set-aside and awarded on July 30, 2025, will be completed by July 31, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is located. Enbrel is a biologic immunosuppressant used to treat rheumatoid arthritis, psoriasis, and other...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,738.89 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/mL syringes. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among eligible vendors. This...